Dr. Munro is a Professor in the Department of Obstetrics and Gynecology of the David Geffen School of Medicine at UCLA, and Director of Gynecologic Services at Kaiser Permanente’s Los Angeles Medical Center. Dr. Munro’s clinical and research interests are oriented to minimally invasive approaches to gynecological disorders with particular interests in surgical education and training as well as the problem of abnormal uterine bleeding including investigation, medical and procedural interventions. He is co-chair of the new FIGO Menstrual Disorders Working Group that has been responsible for the development and publication of the FIGO Nomenclature and Classification Systems for causes of abnormal bleeding in the reproductive years that has been created to facilitate the design and interpretation of related clinical trials. He is also the study chair of STOP-DUB, a US federally funded multicenter randomized clinical trial comparing hysterectomy to endometrial ablation that, to date is the largest of its kind. He has published more than 100 papers, 26 chapters, and four books including Abnormal Uterine Bleeding, released by Cambridge University Press in January of 2010. Dr Munro is also a contributing editor for the Journal of Minimally Invasive Gynecology, an Editor for the Journal of Midlife Women’s Health, and a reviewer for numerous other peer-reviewed specialty journals. He has served the American Association of Gynecologic Laparoscopists (AAGL) as a member of the Board of Trustees (2000-2002) and was the inaugural chair of the AAGL Practice Committee, charged with the development of evidence based practice guidelines related to minimally invasive approaches to gynecology.
As a consultant to the pharmaceutical and device industry, Dr. Munro advises on device development, product research design, new business development, marketing programs, economic modeling, and legal and regulatory issues. These services have culminated in device development and modification, product submissions, and presentations to the relevant FDA panel. Included in Dr. Munro’s current or past corporate clients are a spectrum of companies ranging from early stage to multinational corporate entities, such as Abbvie Inc, Abbott, Bayer HealthCare, TAP Pharmaceuticals, Conceptus Inc, AMAG Pharmaceuticals, Aegea Inc, ConMed Inc, Idolman US and Canada, Bayer HealthCare, Boston Scientific, Channel Medical, Covidien, Karl Storz Endoscopy Americas, Graphic Surgery LLC, Gynesonics Inc, Hologic Inc, Imagyn Inc, Andronic Devices, Novacept, Vifor Pharma, Ethicon Women’s Health and Urology, and Ethicon Endosurgery. For many of these companies, Dr. Munro has been or is a member of the Scientific Advisory Boards and works or has worked with the engineering, regulatory offices, design development staff, and/or the executive group to evaluate and improve performance and safety.
He lives in Tarzana, a Los Angeles suburb, with his wife; they have three adult children.